Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: April 18, 2017
Subject: Regulatory submission of the candidate shingles vaccine, Shingrix, in Japan.
Key Financial Metrics
This filing is a current report regarding a regulatory milestone and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the submission of a New Drug Application (NDA) in Japan by Japan Vaccine Co., Ltd. (a joint venture of GSK and Daiichi Sankyo Co., Ltd.) for Shingrix. This follows prior submissions to the US FDA (October 2016), Canadian authorities, and the European Medicines Agency (November 2016).
Outlook, Commentary, and Risks
- Management Commentary: Dr. Emmanuel Hanon (Head of Vaccines R&D) highlighted that shingles affects up to one in three people in their lifetime and that the vaccine addresses age-related immunity decline. The vaccine is a non-live, subunit vaccine designed to prevent shingles and postherpetic neuralgia (PHN).
- Clinical Data: The submission is based on a Phase III program involving over 37,000 people in 18 countries. Key trials include ZOE-50 (adults 50+) and ZOE-70 (adults 70+), with efficacy data published in the New England Journal of Medicine.
- Regulatory Status: Shingrix is not currently approved for use anywhere in the world. Approval is sought for intramuscular administration in two doses for people aged 50 years or over.
- Risks: The filing includes a cautionary statement that forward-looking statements are subject to risks and uncertainties, including those described in the 2016 Annual Report on Form 20-F, which may cause actual results to differ materially from projections.
Investor Verification Checklist
- Verify the regulatory approval status of Shingrix in the US, EU, and Canada following the 2016 submissions.
- Monitor the timeline for the Japanese regulatory review process and potential approval dates.
- Review the 2016 Annual Report on Form 20-F for detailed risk factors regarding vaccine commercialization and regulatory approvals.
- Assess the commercial potential of the shingles vaccine market in Japan relative to the company's overall vaccines portfolio.